Mortality trends in neonatal ECMO for pulmonary hypoplasia: A review of the Extracorporeal Life Support Organization database from 1981 to 2016
jpedsurg.org shows its articles on its own site.
Read the article on jpedsurg.org ↗Article · Oct 2020 · 1 min read
In brief
In brief
Retrospective analysis of 1,385 neonates with pulmonary hypoplasia treated with ECMO over 35 years shows 33% survival to discharge, with mortality decreasing overall but increasing for renal dysplasia cases. CDH patients had significantly higher mortality than those with renal-associated PH, likely reflecting evolving patient selection criteria as non-ECMO ventilatory support improved.
Written by the GCMD Library team from the article.
Abstract
Background
The purpose of this review is to provide ECMO outcome data for medical personnel who counsel families of patients with pulmonary hypoplasia (PH), often secondary to renal abnormalities. We report diagnoses and outcomes associated with PH in neonates that were treated with ECMO over the past 35 years.
Methods
Retrospective cohort study using the ELSO database for neonates born between 1981 and 2016 with a primary or secondary diagnosis of PH. Five patient groups were created based on ICD-9 codes. Mortality rates were compared and trends over time were investigated.
Results
Thirty-three percent of the 1385 patients survived to discharge. Congenital diaphragmatic hernia (CDH) patients had significantly higher mortality than PH patients secondary to renal dysplasia (p < 0.001). Mortality decreased significantly over time for all groups (p < 0.001). The proportion of patients alive at discharge increased over time for CDH patients (p < 0.001), whereas survival decreased for patients with PH secondary to renal dysplasia (p = 0.012).
Conclusions
Neonates with PH that require ECMO have high mortality rates, which have generally decreased over the past 35 years; however, mortality for neonates with PH secondary to renal dysplasia continues to increase. We speculate that the apparent rise in mortality for these patients is because of changes in patient selection subsequent to improvements in non-ECMO ventilatory support.
Level of evidence
II
